Cochrane中医药系统评价:证据数量与质量孰重?
该文检索Cochrane数据库至2021年5月,纳入104篇中医药系统评价,覆盖70种疾病、1642项原始研究和157,943名参与者。仅5篇得出总体阳性结论,42篇认为证据不足,54篇无法得出明确结论,多数GRADE证据等级为低或极低,49.0%的AMSTAR 2质量评为低。
要点
- 中医药Cochrane系统评价仅5/104得出总体阳性结论,多数证据不充分。
- GRADE评级多为低或极低,仅16篇系统评价报告了方法部分列出的全部结局。
- AMSTAR 2评价49.0%为低质量,未来研究应重质量而非数量。
核心结论
- 尽管中医药广泛应用,其有效性证据仍大多无定论,需高质量试验支撑高质量系统评价。
研究设计与样本
- 检索Cochrane系统评价数据库至2021年5月,纳入104篇中医药系统评价,含1642项原始研究、157,943名参与者。
主要发现
- 104篇系统评价覆盖70种疾病、16个疾病系统,干预包括中药70篇、针灸28篇、中医运动4篇、艾灸2篇。
- 仅5/104篇得出总体阳性结论,42篇认为证据不足,54篇无法得出明确结论。
- GRADE评估报告于41.3%的系统评价中,评级多为低或极低。
- 仅16篇系统评价获得方法部分列出的全部结局结果。
- AMSTAR 2评价51篇(49.0%)为低质量,Web of Science总被引2135次(均值±SD:20.8±21.2),38.5%被指南引用95次。
关键数值与推荐
- GRADE评估报告率41.3%,评级多为低或极低。
- AMSTAR 2低质量系统评价占49.0%(51/104)。
- Web of Science总被引2135次(均值±SD:20.8±21.2)。
- 38.5%的系统评价被指南引用,共95次。
临床怎么用
- 临床决策时应关注中医药系统评价的GRADE证据等级和AMSTAR 2质量,不宜仅凭系统评价数量判断证据强度。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systematic reviews on traditional Chinese medicine (TCM) are constantly increasing. However, if these reviews are to be of practical value, the evidence needs to be relevant, valid, and adequately reported. Cochrane Systematic Reviews (CSRs) are considered as high-quality systematic reviews that can inform health care decision making. Our aim was to provide an overview of the scope, findings, quality and impact of CSRs on the benefits and harms associated with TCM interventions for the treatment and prevention of disease to provide new information for clinical practice and future research. METHODS: The Cochrane Database of Systematic Reviews was searched up to May 2021, and descriptive characteristics were extracted. The correspondence between the questions asked in the CSRs and the available evidence, conclusions and certainty of findings (according to GRADE assessment), methodological quality (AMSTAR 2), and impact (Altmetric Attention Score [AAS], total citations by guideline, and total citations in Web of Science [WoS]) of CSRs were extracted. Tabular and graphical summaries of these descriptive characteristics were constructed. RESULTS: Of 104 CSRs on TCM identified, 70 diseases belonged to 16 disease systems and contained 1642 primary studies with 157,943 participants. Interventions included Chinese herbal medicine (n = 70), acupuncture (n = 28), TCM exercises (n = 4), and moxibustion (n = 2). Among 1642 primary studies, 662 studies included an intervention group treated with at least one TCM therapy and 980 studies included a combination of therapies. Promising outcomes from the 104 CSRs were divided into endpoint outcomes (34 diseases), doctor- or patient-reported outcomes (27 diseases), and surrogate outcomes (37 diseases). Despite the presence of promising outcomes, only 5/104 CSRs drew overall positive conclusions, 42 CSRs concluded the evidence was insufficient, and 54 failed to draw firm conclusions. GRADE assessments were reported in 41.3% of the CSRs, and the ratings were mostly low or very low. Comparing the questions asked and results obtained, there was frequently a lack of information about specific outcomes. Only 16 CSRs obtained results for all outcomes listed in the methods section. According to AMSTAR 2, 51 CSRs (49.0%) were of low quality. The total number of citations in the WoS was 2135 (mean ± SD: 20.8 ± 21.2), and 38.5% of the CSRs had been cited in guidelines 95 times. CONCLUSION: Although TCM is commonly used, evidence of its effectiveness remains largely inconclusive. Rigorous high-quality trials are needed to support the performance of high-quality reviews and to increase the evidence base. It is critical to emphasize quality over quantity in future TCM research.
引用
- Dai Z, Liao X, Wieland LS, et al. Cochrane systematic reviews on traditional Chinese medicine: What matters-the quantity or quality of evidence? Phytomedicine. 2022. PMID: 35104758. doi:10.1016/j.phymed.2021.153921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。